Pulmonary Embolism Clinical Trial
Official title:
Strategies for Suspected Pulmonary Embolism in Emergency Departments - SPEED Study
Verified date | February 2009 |
Source | University Hospital, Angers |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
Aims: 1) To evaluate the effectiveness of two interventions aimed at improving the
management of patients with suspected pulmonary embolism: Written guidelines and
Computer-Assisted Decision Support (CADS). 2) To evaluate the impact of electronic reminders
on the appropriateness of the treatment of patients with suspected PE
Design: Pragmatic, unblinded, cluster randomised controlled study.
Setting: 20 French Emergency Departments
Patients: Out patients suspected of having pulmonary embolism
Methods: Emergency physicians will prospectively complete a standardized electronic form on
Personal Data Assistant (PDA), including patients' characteristics, the clinical probability
if assessed, the diagnostic tests performed, the treatments initiated and the final
diagnostic and therapeutic decisions. Patients will be interviewed at the end of a 3-month
follow-up period using a standardized questionnaire.
The reference rate of appropriateness of the diagnostic management before intervention will
be assessed in each centre. At the end of this preliminary period, the centres will be
randomized in two fold two groups according to a factorial design with stratification on
their reference level of appropriateness. Half of the centres will have written guidelines
and half a Computer-Assisted Decision Support for the diagnosis of PE on the PDA. In each of
these two main groups, half of the centres will have electronic reminders on their PDA
concerning the treatment of PE.
Judgment criteria
Main : Rate of strategies considered as validated according to the results of the systematic
review and meta-analysis.3
Secondary judgment criteria (diagnosis):
- Rate of strategies considered as validated or acceptable according to the opinion of
international advisors.
- Rate of thromboembolic-events during a 3-month follow-up period in patients for whom
pulmonary embolism will be ruled out
- Costs of the diagnostic management
Secondary judgment criteria (treatment):
- Delay between Emergency Department admission and the first dose of antithrombotic
treatment in patients with high clinical probability of PE according to the Revised
Geneva Score
- Rate of inappropriate treatment according to international recommendations for patients
with confirmed PE.
Number of patients: By estimating that the rate of appropriateness would be 55% in the
"written guidelines" group, 1331 patients are necessary to highlight an absolute superiority
of 15% in the "CADS" group (rate of conformity of 70%).
The number of patients will be adjusted at the end of the preliminary period according to
the level of appropriateness before interventions considering that it will improve less than
5% in the "written guidelines" group.
Status | Completed |
Enrollment | 1331 |
Est. completion date | September 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - patient with suspected pulmonary embolism - prescription of a specific paraclinical diagnostic investigation or start of a specific treatment for pulmonary embolism Exclusion Criteria: - confirmation or exclusion of pulmonary embolism before admission in emergency department - confirmation of deep venous thrombosis before admission in emergency department - suspicion of pulmonary embolism during hospitalization (in-patient) - suspicion of pulmonary embolism without investigation realization - patient already included in the study - patient refusing the utilization of his data for the study |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
France | H Argenteuil | Argenteuil | |
France | UH Besançon | Besançon | |
France | H Bethune | Bethune | |
France | UH Ambroise Pare | Boulogne Billancourt | |
France | UH Caen | Caen | |
France | H Chalons en Champagne | Chalons-en-Champagne | |
France | H Chateauroux | Chateauroux | |
France | H Compiegne | Compiegne | |
France | UH Dijon | Dijon | |
France | H Dreux | Dreux | |
France | UH Grenoble | Grenoble | |
France | H Langres | Langres | |
France | H le Mans | Le Mans | |
France | H Lons le Saunier | Lons le Saunier | |
France | UH Nancy | Nancy | |
France | UH La Pitie Salpetriere | Paris | |
France | H Roanne | Roanne | |
France | H Saint Nazaire | Saint Nazaire | |
France | H Thouars | Thouars | |
France | UH Toulouse | Toulouse |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers | Ministry of Health, France |
France,
Roy PM, Colombet I, Durieux P, Chatellier G, Sors H, Meyer G. Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism. BMJ. 2005 Jul 30;331(7511):259. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | rate of agreement between the diagnostic criteria applied in daily practice and those validated in the scientific literature | |||
Secondary | -(diagnostic intervention) Rate of strategies considered as validated or acceptable according to the opinion of international advisors. | |||
Secondary | - (diagnostic intervention) Rate of thromboembolic-events during a 3-month follow-up period in patients for whom pulmonary embolism will be ruled out | |||
Secondary | - (diagnostic intervention) Costs of the diagnostic management | |||
Secondary | - (therapeutic reminders) Delay between Emergency Department admission and the first dose of antithrombotic treatment in patients with high clinical probability of PE according to the Revised Geneva Score | |||
Secondary | - (therapeutic reminders)Rate of inappropriate treatment according to international recommendations for patients with confirmed PE. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 |